Aurobindo receives FDA nod for generic Myfortic DR Tablets
Mycophenolic Acid DR Tablets are indicated for prophylaxis of organ rejection in certain pediatric and adult kidney transplant patients.
Aurobindo has obtained the Food and Drug Administration’s green light for Mycophenolic Acid DR Tablets, 180 mg and 360 mg, which are the generic of Novartis’ Myfortic DR.
Mycophenolic Acid DR Tablets are indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.
[Read more: Aurobindo given FDA approval for Isotretinoin Capsules]
Mycophenolic Acid DR Tablets has a market value of roughly $70 million for the 12 months ending December 2023, per IQVIA.